In an open international competition, the bellygenes project proposal was recently selected and received approval to access genotype and phenotype data from the European consortium BioMolecular resources Research Infrastructure - large prospective cohorts (http://www.bbmri-lpc.org), which includes several major European biobanks and general population-based cohorts.
Our goal is to exploit genetic information and e-data from several bbmri-lpc cohorts, in order to identify primary IBS genetic risk factors in the general population. We will adopt ad-hoc strategies to survey IBS in these cohorts, using Rome Criteria and data on self-reported conditions from questionnaires, as well as electronic medical records to extract IBS diagnoses from national healthcare registries based on the International Classification of Diseases (ICD10) codes. Through a series of country-specific genome-wide association studies (GWAS) and their meta-analyses we will study IBS genetic risk factors in a total target population largely exceeding 800,000 Europeans.
In addition, we will also look into the genetics of IBS-related relevant phenotypes (endophenotypes) such as stool frequency and consistency, which are of clinical relevance and often altered in IBS patients. We have established a vast collaborative network of expert IBS clinicians, for replication and independent studies in well-characterized case-control cohorts from world-leading tertiary centers.
The outcome of this project will reveal pathophysiological pathways that can help explain the etiology of IBS, inform a molecular reclassification of patients, and ultimately provide novel biological targets for increased therapeutic precision.
Updates with news and results from our activities will be posted on this website.
Our goal is to exploit genetic information and e-data from several bbmri-lpc cohorts, in order to identify primary IBS genetic risk factors in the general population. We will adopt ad-hoc strategies to survey IBS in these cohorts, using Rome Criteria and data on self-reported conditions from questionnaires, as well as electronic medical records to extract IBS diagnoses from national healthcare registries based on the International Classification of Diseases (ICD10) codes. Through a series of country-specific genome-wide association studies (GWAS) and their meta-analyses we will study IBS genetic risk factors in a total target population largely exceeding 800,000 Europeans.
In addition, we will also look into the genetics of IBS-related relevant phenotypes (endophenotypes) such as stool frequency and consistency, which are of clinical relevance and often altered in IBS patients. We have established a vast collaborative network of expert IBS clinicians, for replication and independent studies in well-characterized case-control cohorts from world-leading tertiary centers.
The outcome of this project will reveal pathophysiological pathways that can help explain the etiology of IBS, inform a molecular reclassification of patients, and ultimately provide novel biological targets for increased therapeutic precision.
Updates with news and results from our activities will be posted on this website.